Akari Therapeutics Plc P/E
Cos'è P/E di Akari Therapeutics Plc?
P/E di Akari Therapeutics Plc è 0.00
Qual è la definizione di P/E?
Il rapporto prezzo / utili è il rapporto tra il prezzo delle azioni di una società e l'utile per azione della società calcolato su dodici mesi.
The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.
P/E di aziende nel Health Care settore su NASDAQ rispetto a Akari Therapeutics Plc
Cosa fa Akari Therapeutics Plc?
akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.
Aziende con p/e simili a Akari Therapeutics Plc
- Richland Resources International ha P/E di N/A
- Safeplus International ha P/E di N/A
- China Yanyuan Yuhui Natl Ed Grp ha P/E di N/A
- Acusphere ha P/E di N/A
- American Oriental Bioengineering ha P/E di N/A
- Gourmet Provisions International ha P/E di N/A
- Akari Therapeutics Plc ha P/E di 0.00
- SEL Manufacturing ha P/E di 0.00
- China Zhong Qi Hldgs ha P/E di 0.00
- MedSmart ha P/E di 0.00
- Panbela Therapeutics ha P/E di 0.00
- Epic ha P/E di 0.00
- 2574 ha P/E di 0.00